|
 |
European Biopharmaceutical Review
|
| Vaccines are a group of products that include some of the oldest biological pharmaceutical entities. They are also an area where new techniques and manufacturing technologies are giving rise to significant growth. While eradication of some historic diseases has led to a lower need for prophylaxis, the resurgent threat of bioterrorism has given impetus to finding new and rapid methods for producing vaccines against a range of new and old threats, such as Anthrax. |
Read full article >>
|
 |
 |
 |
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
 |

 |
Industry Events |
 |
BioPh Europe
5-7 October 2010, Paris, France
All companies and organisations dealing with the research and development of new treatment methods made through biotechnological processes or which are derived from or use live organisms will benefit from the mix of exhibition, seminars and 121 partnering meetings at BioPh. BioPh Europe 2010 at Paris Nord Villepinte will offer you unrivalled networking and commercial opportunities in the world of drug research and manufacturing.
More info >> |
|
 |
News and Press Releases |
 |
Glycotope GMBH
Berlin, Germany – August 4, 2010
Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope´s next generation antibody CetuGEX (GT-MAB 5.2-GEX) for the treatment of various solid cancers.
More info >> |
|
 |